Site-specific structural modification of monoclonal antibodies for therapeutic application

Author：  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.10, Iss.2, 2000-02, pp. : 251-253

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

By Dirks Nathanael L.   Meibohm Bernd  

Clinical Pharmacokinetics, Vol. 49, Iss. 10, 2010-10 ,pp. : 633-659

Adis International

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

By Keizer Ron J.   Huitema Alwin D.R.   Schellens Jan H.M.   Beijnen Jos H.  

Clinical Pharmacokinetics, Vol. 49, Iss. 8, 2010-08 ,pp. : 493-507

Adis International

Access to resources Recommend Favorite

Pharmacogenetics and pharmacogenomics of therapeutic monoclonal antibodies

By Yan Li   Davis Hugh M  

Pharmacogenomics, Vol. 7, Iss. 7, 2006-10 ,pp. : 961-964

Future Medicine

Access to resources Recommend Favorite

Therapeutic Potential of Monoclonal Antibodies in Myocardial Reperfusion Injury

By Nigam A.   Kopecky S.L.  

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 6, 2002-01 ,pp. : 367-376

Adis International

Access to resources Recommend Favorite

Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials

By  

Medicinal Chemistry, Vol. 14, Iss. 2, 2018-02 ,pp. : 144-154

Bentham Science Publishers

Access to resources Recommend Favorite